Institutional Repository

Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment

Show simple item record

dc.contributor.advisor Maja, Todd Mamutle Mavis
dc.contributor.author Haumba, Samson Malwa
dc.date.accessioned 2016-09-08T13:58:31Z
dc.date.available 2016-09-08T13:58:31Z
dc.date.issued 2015-06
dc.identifier.citation Haumba, Samson Malwa (2015) Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment, University of South Africa, Pretoria, <http://hdl.handle.net/10500/21189> en
dc.identifier.uri http://hdl.handle.net/10500/21189
dc.description.abstract The purpose of the study was to develop best practice guidelines to prevent permanent hearing loss associated with the management of multi-drug resistant tuberculosis (MDR-TB) through raised awareness and monitoring. The Human Immunodeficiency Virus (HIV) and MDR-TB are global public health problems requiring urgent scale-up of treatment services. Irreversible sensorineural hearing loss (SNHL) is one of the adverse drug reactions of the current World Health Organization (WHO) recommended MDR-TB chemotherapy fuelling another public health problem, that disabling hearing loss, which is the second highest contributor of Years Lived with Disability (YLD) according to the World Health Report (2003). Expansion of MDR-TB treatment threatens to increase incidence of SNHL unless there is urgent implementation of intervention towards preservation of hearing for patients on treatment. This empirical study determined and documented the incidence of SNHL in HIV positive and HIV negative patients on MDR-TB treatment, the risk factors for SNHL, from the time treatment initiation to SNHL. Based on the findings, developed and improved the understanding of best practice guidelines for monitoring and prevention of MDR-TB treatment-related SNHL. The empirical study recruited a cohort of 173 patients with normal hearing status, after diagnosis with MDR-TB and enrolled on MDR-TB therapy over thirteen month period. Patients in the cohort received monthly hearing sensitivity testing during the intensive MDR-TB therapy when injectable aminoglycoside antibiotics are part of the treatment regimen. The three study endpoints included completion of the eight-month intensive treatment phase without developing hearing loss, development incident hearing loss or loss to follow up. Data was analysed using STATA statistical software and summarised using frequencies, means, proportions, and rates. The study documented incidence of SNHL, time to hearing loss and risk factors for hearing loss. Recommendations to prevent and monitor hearing loss are made based on the the study findings. en
dc.format.extent 1 online resource (various pagings) : illustrations (some color)
dc.language.iso en en
dc.subject Sensorineural hearing loss en
dc.subject Cochleotoxicity en
dc.subject Multi drug resistant tuberculosis en
dc.subject Aminoglycoside antibiotics en
dc.subject Audiometry en
dc.subject Incidence en
dc.subject Time-to-event en
dc.subject Best practice guidelines en
dc.subject Prevention en
dc.subject Monitoring en
dc.subject.ddc 610.730693096825
dc.subject.lcsh Deafness -- Prevention
dc.subject.lcsh Tuberculosis -- Alternative treatment -- Swaziland
dc.subject.lcsh Multidrug-resistant tuberculosis -- Treatment -- Swaziland
dc.subject.lcsh Deaf -- Services for -- Swaziland
dc.subject.lcsh Hearing clinics -- Management -- Swaziland
dc.subject.lcsh Neuman systems model
dc.subject.lcsh Public health -- Swaziland
dc.title Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment en
dc.type Thesis en
dc.description.department Health Studies
dc.description.degree D. Litt. et Phil. (Health Studies)


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UnisaIR


Browse

My Account

Statistics